Skip to main contentSkip to navigation
Sirius Investors

IPHA Stock: Innate Pharma S.A. Stock Price, Analysis & Insights

Get live IPHA stock price $1.77, comprehensive Innate Pharma S.A. stock analysis, charts, news, and expert forecast. Real-time IPHA stock data and investment insights.

1.77
0.57%Today
IPHAInnate Pharma S.A. • NASDAQ Global Select • Healthcare
Market Cap
166.21M
Volume
2.01K
52W High
2.63
52W Low
1.17

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications ...

Company Information

CEO
Jonathan E. Dickinson
Sector
Healthcare
Industry
Biotechnology
Employees
181

Contact Information

Address
117, Avenue de Luminy
Country
FR

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Innate Pharma S.A. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Innate Pharma S.A.
  • Investors should consider how Innate Pharma S.A. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

166.21M

P/E Ratio (TTM)

-2.81

Beta

0.89

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.